← Pharmacy curriculum
Module 20812 lessonsRxPrep 2023 alcohol-associated liver disease, withdrawal, AUD medication, and nutrition material, reconciled with the 2024 ACG guideline, 2019 AASLD guidance, 2020 ASAM withdrawal guideline, and current medication labeling

Alcohol-Associated Liver Disease

Move from alcohol exposure and hepatic injury to safe withdrawal, evidence-based AUD treatment, alcohol-associated hepatitis, nutrition, transplant selection, and sustained recovery.

01

Explain alcohol metabolism and liver injury.

02

Screen for AUD and fibrosis without stigma.

03

Build an integrated recovery plan.

04

Assess and treat withdrawal safely.

05

Prevent Wernicke encephalopathy and malnutrition.

06

Select AUD medication for liver and kidney status.

07

Diagnose alcohol-associated hepatitis.

08

Use MELD and Lille to govern corticosteroids.

09

Integrate NAC, nutrition, and organ support.

10

Manage cirrhosis complications in parallel.

11

Explain modern transplant selection.

12

Build closed-loop longitudinal care.

208.01

Follow Alcohol From Metabolism to Fibrosis

The same exposure can produce reversible steatosis, inflammatory hepatitis, progressive fibrosis, or decompensated cirrhosis depending on host and coexisting disease.

What to learn
  • ADH
  • ALDH
  • Acetaldehyde
  • NADH
  • Fibrosis
Liver and recovery

spectrum mechanism

Connect hepatic injury, withdrawal safety, addiction treatment, nutrition, and long-term recovery without stigma.

Map metabolism

Alcohol dehydrogenase converts ethanol to acetaldehyde, and aldehyde dehydrogenase converts acetaldehyde to acetate. Excess NADH shifts lipid metabolism toward hepatic fat accumulation.

Map cellular injury

Acetaldehyde adducts, oxidative stress, mitochondrial dysfunction, endotoxin signaling, cytokines, and immune activation injure hepatocytes and activate fibrogenesis.

Name the spectrum

Steatosis may improve with abstinence. Steatohepatitis, alcohol-associated hepatitis, fibrosis, cirrhosis, and ACLF reflect progressively different risk states.

Identify modifiers

Female sex, obesity, diabetes, smoking, gastric bypass, genetic susceptibility, malnutrition, and viral or metabolic liver disease increase progression risk.

0 of 1 answered
01What metabolic shift promotes steatosis?
Answer every question to submit.
208.02

Screen Without Stigma and Stage Without Guessing

Neutral questions, validated tools, and context-aware fibrosis testing produce better evidence than appearance or assumptions.

What to learn
  • AUDIT-C
  • Standard drink
  • PEth
  • FIB-4
  • Elastography
Liver and recovery

screening staging

Connect hepatic injury, withdrawal safety, addiction treatment, nutrition, and long-term recovery without stigma.

Use validated screening

AUDIT-C is a brief screen, while the full AUDIT adds consequences and dependence features. A positive screen prompts assessment rather than automatic diagnosis.

Quantify the pattern

Translate beverage size and alcohol content into standard drinks. Capture binge pattern, duration, periods of abstinence, and recent change.

Use biomarkers transparently

PEth, urine EtG or EtS, and other markers have different windows. Explain purpose, consent, false interpretations, and how results will affect care.

Stage fibrosis carefully

FIB-4 and transient elastography are useful, but active inflammation and alcohol-related thrombocytopenia can inflate estimates. Repeat or escalate uncertain results.

0 of 1 answered
01What is the best response to a positive AUDIT-C?
Answer every question to submit.
208.03

Treat Alcohol Use Disorder as the Disease Driver

Withdrawal management is only the first transition in recovery, not the end of treatment.

What to learn
  • Motivational care
  • Medication
  • Behavioral therapy
  • Community support
  • Harm reduction
Liver and recovery

recovery system

Connect hepatic injury, withdrawal safety, addiction treatment, nutrition, and long-term recovery without stigma.

Center abstinence without blame

Sustained abstinence gives the liver its best chance to recover. Use person-first language and frame recurrence as a signal to intensify treatment rather than discharge the patient.

Use brief intervention

Ask permission, connect alcohol to the patient's goals, assess readiness, offer choices, and agree on a specific next step.

Combine treatments

Medication, cognitive or motivational therapies, peer support, contingency approaches, and social services can reinforce one another.

Close the handoff

Schedule addiction and hepatology follow-up, provide medication supply, address transportation and cost, and name an urgent-contact pathway.

0 of 1 answered
01Which plan best treats AUD in ALD?
Answer every question to submit.
208.04

Prevent Seizure, Delirium, and Oversedation

Withdrawal severity and treatment setting must be predicted before symptoms peak.

What to learn
  • CIWA-Ar
  • Seizure
  • Delirium
  • Benzodiazepine
  • Phenobarbital
Liver and recovery

withdrawal

Connect hepatic injury, withdrawal safety, addiction treatment, nutrition, and long-term recovery without stigma.

Stratify risk

Prior seizure or delirium, repeated withdrawals, older age, severe medical illness, concurrent sedatives, pregnancy, unstable vitals, and poor support increase risk.

Use scales within limits

CIWA-Ar supports symptom-triggered care in communicative patients but is unreliable in delirium, severe illness, intubation, or overlapping HE.

Use benzodiazepines first line

Benzodiazepines prevent seizures and delirium. In significant liver dysfunction, lorazepam or oxazepam reduces dependence on oxidative hepatic metabolism.

Reserve advanced regimens

Phenobarbital requires experienced clinicians and close monitoring. Clonidine, dexmedetomidine, and beta blockers are adjuncts and do not prevent seizures alone.

0 of 1 answered
01Which benzodiazepine is often favored in significant liver dysfunction?
Answer every question to submit.
208.05

Protect the Brain and Rebuild Metabolic Reserve

Thiamine deficiency, electrolyte depletion, sarcopenia, and refeeding risk can coexist before the liver diagnosis is complete.

What to learn
  • Wernicke encephalopathy
  • Thiamine
  • Magnesium
  • Phosphate
  • Protein
Liver and recovery

thiamine nutrition

Connect hepatic injury, withdrawal safety, addiction treatment, nutrition, and long-term recovery without stigma.

Do not wait for the triad

Confusion, ataxia, and ocular findings are the classic Wernicke triad, but many patients do not show all three. Treat promptly when risk and findings support it.

Choose the route from risk

Parenteral thiamine is preferred with malnutrition, malabsorption, critical illness, severe withdrawal, or suspected Wernicke disease. Prevention and treatment doses are not interchangeable.

Correct partners selectively

Check magnesium because it supports thiamine-dependent enzymes. Correct documented severe phosphate, potassium, and magnesium abnormalities with monitoring.

Feed adequately

Many patients need about 35 kcal/kg/day and 1.2 to 1.5 g/kg/day protein. Add supplements and enteral nutrition when oral intake remains inadequate.

0 of 1 answered
01Should urgent glucose be delayed until thiamine is given?
Answer every question to submit.
208.06

Select Recovery Medication Through Organ Function

The older list of naltrexone, acamprosate, and disulfiram is not a safe menu for every patient with liver disease.

What to learn
  • Acamprosate
  • Naltrexone
  • Baclofen
  • Gabapentin
  • Topiramate
Liver and recovery

aud medications

Connect hepatic injury, withdrawal safety, addiction treatment, nutrition, and long-term recovery without stigma.

Use acamprosate for abstinence support

Acamprosate is renally eliminated and taken three times daily. Reduce the dose in moderate renal impairment and avoid it when creatinine clearance is 30 mL/min or less.

Use naltrexone for heavy-drinking reduction

Oral or extended-release naltrexone can be considered in appropriate compensated ALD. Exclude opioids, acute hepatitis or liver failure, and create a pain plan.

Use baclofen deliberately

Baclofen is off label but has ALD-specific evidence. Start low, titrate gradually, adjust for kidney function, and monitor sedation, falls, and cognition.

Avoid disulfiram in ALD

Current ACG guidance advises against disulfiram across ALD because of hepatotoxicity and limited benefit. Gabapentin or topiramate may be selected off label with CNS and renal safeguards.

0 of 1 answered
01Which medication should be avoided across the ALD spectrum?
Answer every question to submit.
208.07

Diagnose Alcohol-Associated Hepatitis as a Syndrome

Acute jaundice after sustained heavy exposure is a clinical pattern that still requires exclusion of competing causes and infection.

What to learn
  • Jaundice
  • Bilirubin
  • AST and ALT
  • Infection
  • Biopsy
Liver and recovery

hepatitis diagnosis

Connect hepatic injury, withdrawal safety, addiction treatment, nutrition, and long-term recovery without stigma.

Recognize the phenotype

Typical AH includes recent onset or worsening jaundice, bilirubin elevation, AST greater than ALT with usually moderate enzyme values, and sustained heavy alcohol exposure.

Exclude alternatives

Review drugs and supplements, viral hepatitis, biliary obstruction, ischemia, autoimmune disease, sepsis, vascular disease, and metabolic injury.

Search complications

Assess ascites with diagnostic paracentesis when indicated, cultures and imaging from presentation, AKI, bleeding, HE, nutrition, and ACLF.

Use biopsy selectively

Biopsy is not required for a classic high-confidence presentation but may be useful when uncertainty would change corticosteroid or transplant decisions.

0 of 1 answered
01Does AST greater than ALT prove alcohol-associated hepatitis?
Answer every question to submit.
208.08

Make Corticosteroid Exposure Earn Its Risk

Prednisolone benefits a selected severe-AH subgroup only when contraindications are controlled and early response is demonstrated.

What to learn
  • MELD
  • Maddrey DF
  • Prednisolone
  • Lille
  • Infection
Liver and recovery

steroid lille

Connect hepatic injury, withdrawal safety, addiction treatment, nutrition, and long-term recovery without stigma.

Use current severity framing

Current ACG guidance uses MELD above 20 to define severe AH for corticosteroid consideration. Maddrey DF remains familiar but is laboratory dependent.

Screen contraindications

Evaluate uncontrolled infection, active GI bleeding, severe kidney failure, pancreatitis, and other steroid hazards. Treated infection may permit later reassessment.

Give the selected regimen

Prednisolone 40 mg daily is the common oral regimen for up to 4 weeks when appropriate. Do not use pentoxifylline as a substitute.

Stop nonresponse

Calculate Lille at day 4 or 7. A score at least 0.45 indicates poor response and generally supports stopping corticosteroids to reduce infection risk.

0 of 1 answered
01A day-7 Lille score is 0.62. What is the usual action?
Answer every question to submit.
208.09

Combine Disease Therapy With Organ Support

NAC, nutrition, infection surveillance, kidney protection, and AUD treatment operate alongside corticosteroid selection.

What to learn
  • NAC
  • Nutrition
  • AKI
  • Infection
  • ACLF
Liver and recovery

nac support

Connect hepatic injury, withdrawal safety, addiction treatment, nutrition, and long-term recovery without stigma.

Use NAC as an adjunct

The 2024 ACG guideline recommends intravenous NAC with corticosteroids in severe AH. It is adjunctive rather than a stand-alone cure.

Feed early

Oral nutrition and supplements are preferred. Use enteral feeding when intake remains inadequate, including with stable varices when there is no active bleeding or recent banding contraindication.

Avoid universal antibiotics

Screen carefully and treat documented or strongly suspected infection, but do not give prophylactic antibiotics universally to every severe-AH admission.

Track organ failure

Creatinine, oxygenation, pressure, mental status, infection, bleeding, sodium, and bilirubin trajectory determine ICU, transplant, and palliative pathways.

0 of 1 answered
01What is the current role of IV NAC in severe AH?
Answer every question to submit.
208.10

Treat Established Cirrhosis in Parallel

Abstinence can improve prognosis, but portal hypertension, ascites, HE, HRS, bleeding, and HCC risk still require full cirrhosis care.

What to learn
  • Ascites
  • SBP
  • Varices
  • HE
  • HCC
Liver and recovery

cirrhosis complications

Connect hepatic injury, withdrawal safety, addiction treatment, nutrition, and long-term recovery without stigma.

Manage fluid and infection

Use diagnostic paracentesis for new or admitted ascites, sodium and diuretic plans, albumin with large-volume paracentesis, and SBP treatment or prophylaxis when indicated.

Prevent bleeding

Assess CSPH and variceal risk for nonselective beta blockade or endoscopic strategy, and use the acute bleeding bundle when hemorrhage occurs.

Protect cognition and kidneys

Treat HE precipitants with lactulose and selected rifaximin, avoid sedative accumulation, and distinguish HRS-AKI from shock or structural kidney disease.

Continue surveillance

Provide HCC surveillance about every 6 months, vaccines, nutrition, bone health, medication stewardship, and timely transplant referral.

0 of 1 answered
01Does abstinence end HCC surveillance in established cirrhosis?
Answer every question to submit.
208.11

Select Transplant Candidates With Evidence, Not a Calendar

Early transplant can be lifesaving for selected severe-AH nonresponders, and modern evaluation is multidimensional.

What to learn
  • Early transplant
  • Relapse risk
  • Support
  • Insight
  • Equity
Liver and recovery

transplant ethics

Connect hepatic injury, withdrawal safety, addiction treatment, nutrition, and long-term recovery without stigma.

Move beyond six months alone

A fixed six-month abstinence rule does not accurately predict relapse and can exclude patients who will die before reaching it.

Use multidisciplinary evidence

Evaluate prior treatment, relapse pattern, insight, psychiatric disease, other substances, social support, housing, adherence, coping, and willingness to engage.

Plan post-transplant recovery

Continue AUD medication when appropriate, behavioral care, biomarker monitoring with transparency, family support, and rapid intervention for recurrence.

Protect equity

Apply documented center criteria consistently and separate moral judgment from medical and psychosocial risk assessment.

0 of 1 answered
01What should transplant candidacy not depend on alone?
Answer every question to submit.
208.12

Build a Closed-Loop Liver and Recovery Plan

The highest-quality plan treats withdrawal, AUD, liver injury, nutrition, complications, and social conditions as one system.

What to learn
  • Withdrawal
  • AUD medication
  • Liver state
  • Nutrition
  • Follow-up
Liver and recovery

integrated case

Connect hepatic injury, withdrawal safety, addiction treatment, nutrition, and long-term recovery without stigma.

Stabilize immediate risk

Assess withdrawal, suicidality, intoxication, trauma, infection, bleeding, glucose, electrolytes, thiamine need, and level of care.

Define liver disease

Document AH confidence, fibrosis, compensation, MELD, organ failures, infection, HCC status, and transplant indication.

Start recovery treatment

Choose medication through liver, kidney, opioid, cognition, and goal context. Add behavioral care and practical support before discharge.

Measure what matters

Track alcohol goals, adherence, recurrence, liver function, nutrition, complications, quality of life, and re-entry without punitive discharge.

0 of 1 answered
01Which discharge plan is strongest after alcohol withdrawal with ALD?
Answer every question to submit.

Check the connections.

Each attempt draws 10 questions from the complete 100 question bank.

100 questions in this module bank10 questions per attempt

Each attempt draws a fresh set and rearranges the answer choices.

Current clinical foundation.

Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.

  1. 2024 ACG Clinical Guideline for Alcohol-Associated Liver Disease
  2. AASLD Alcohol-Associated Liver Disease Practice Guidance
  3. ASAM Alcohol Withdrawal Management Guideline
  4. AASLD Steroids, Maddrey, and Lille Review
  5. Current CAMPRAL Prescribing Information
PharmacyOpen tools